Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFEO pilot study
2022-502524-41-00Phase 2Authorised
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, ipilimumab and ascorbic acid in colon cancer, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Pathological response rate. Planned start Mar 2023; status: authorised.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2022-502524-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502524-41-00.